Allogeneic human mesenchymal stem cells(University of Miami)(Allogeneic human mesenchymal stem cells(University of Miami))

概要

基本信息

药物类型

间充质干细胞疗法

别名

Allo-hMSCs

靶点-

作用机制

干细胞替代物

治疗领域

其他疾病神经系统疾病心血管疾病

在研适应症-

非在研适应症

急性缺血性卒中难治性抑郁症

原研机构

University of Miami

在研机构-

非在研机构

University of Miami

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

18

项与 Allogeneic human mesenchymal stem cells(University of Miami) 相关的临床试验

NCT04476901 / Recruiting临床2期IIT

A Phase IIB Randomized, Placebo-Controlled, Multicenter Study of the Comparative Efficacy and Safety of Administration of Allogeneic-MSC Versus Placebo in Patients with Non- Ischemic Dilated Cardiomyopathy

The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy.

开始日期2021-05-07

申办/合作机构

University of Miami

[+2]

NCT03487731 / Withdrawn临床1/2期IIT

A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to EValuate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain

The study is a phase I/II trial where allogeneic human mesenchymal stem cells (hMSCs) are injected intracfect into the lumbar facet joints. Forty (40) subjects are scheduled to undergo injection after meeting all inclusion/exclusion criteria will be evaluate at baseline.

开始日期2020-12-01

申办/合作机构

University of Miami

IRCT20160809029275N2 / Recruiting临床2期IIT

Safety and immuno-modulation evaluation of treatment with intravenous and spinal cord injections of of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis (ALS).

开始日期2020-06-21

申办/合作机构

Mashhad University of Medical Sciences

100 项与 Allogeneic human mesenchymal stem cells(University of Miami) 相关的临床结果

登录后查看更多信息

100 项与 Allogeneic human mesenchymal stem cells(University of Miami) 相关的转化医学

登录后查看更多信息

100 项与 Allogeneic human mesenchymal stem cells(University of Miami) 相关的专利（医药）

登录后查看更多信息

10

项与 Allogeneic human mesenchymal stem cells(University of Miami) 相关的文献（医药）

2021-02-01·Clinical Endocrinology2区 · 医学

Long‐term magnesium supplementation improves glucocorticoid metabolism: A post‐hoc analysis of an intervention trial

2区 · 医学

Article

作者: de Borst, Martin H. ; Bakker, Stephan J. L. ; Joris, Peter J. ; Schutten, Joëlle C. ; Mensink, Ronald P. ; Post, Adrian ; van Beek, André P. ; Minović, Isidor

AbstractObjectiveIncreasing magnesium intake might reduce the risk of cardiovascular disease (CVD). Whether potential effects on cortisol contribute to these beneficial effects on cardiovascular health remains unclear. We therefore studied effects of long‐term oral magnesium supplementation on glucocorticoid metabolism, specifically on the excretion of urinary cortisol, cortisone and their metabolites, as well as on the ratios reflecting enzymatic activity of 11β‐hydroxysteroid dehydrogenases (11β‐HSDs) and A‐ring reductases.DesignA post‐hoc analysis of a randomized trial with allocation to a magnesium supplement (350 mg/day) or a placebo for 24‐week.PatientsForty‐nine overweight men and women, aged between 45 and 70 years.MeasurementsCortisol, cortisone and their metabolites (tetrahydrocortisol [THF], allo‐tetrahydrocortisol [allo‐THF] and tetrahydrocortisone [THE]) were measured in 24‐h urine samples. Enzymatic activities of 11β‐HSD overall and of 11β‐HSD type 2 were estimated as the urinary (THF + allo‐THF [THFs])/THE and cortisol/cortisone ratios, respectively. A‐ring reductase activity was assessed by ratios of THF/allo‐THF, allo‐THF/cortisol, THF/cortisol and THE/cortisone.ResultsAfter 24‐week, urinary cortisol excretion was decreased in the magnesium group as compared with the placebo group (−32 nmol/24‐h, 95% CI: −59; −5 nmol/24‐h, p = .021). Ratios of THFs/THE and cortisol/cortisone were decreased following magnesium supplementation by 0.09 (95% CI: 0.02; 0.17, p = .018) and 0.10 (95% CI: 0.03; 0.17, p = .005), respectively. No effects were observed on A‐ring reductase activity.ConclusionsWe observed a beneficial effect of magnesium supplementation towards a lower 24‐h urinary cortisol excretion together with an increased activity of 11β‐HSD type 2. Our findings may provide another potential mechanism by which increased magnesium intake lowers CVD risk (ClinicalTrials.gov identifier: NCT02235805).

2020-06-01·Transplantation2区 · 医学

LPS-induced Airway-centered Inflammation Leading to BOS-like Airway Remodeling Distinct From RAS-like Fibrosis in Rat Lung Transplantation

2区 · 医学

Article

作者: Hamaji, Masatsugu ; Yoshizawa, Akihiko ; Aoyama, Akihiro ; Date, Hiroshi ; Saito, Masao ; Gochi, Fumiaki ; Sato, Masaaki ; Urushiyama, Hirokazu ; Chen-Yoshikawa, Toyofumi F ; Sonobe, Makoto ; Takahagi, Akihiro ; Miyamoto, Ei ; Terasaki, Yasuhiro

Background.Localization of inflammatory stimuli may direct lung allografts to different phenotypes of chronic dysfunction, such as bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndrome (RAS). We hypothesized that airway stimulation with lipopolysaccharide (LPS) in rats leads to airway-centered inflammation similar to human BOS.Methods.Rat left lung transplantation was conducted (donor: Brown Norway, recipient: Lewis). Allotransplant recipients received cyclosporine A (CsA) until postoperative day 56 with airway instillation of LPS (Allo-LPS, n = 8), phosphate buffered saline (Allo-PBS, n = 5) from days 35 to 46 (3 times a wk), or no further treatment (n = 4). Some allotransplant recipients received CsA until day 14 and were immunosuppression free after day 15 until day 56. Bronchial and pleural fibrosis were semiquantified; alveolar fibrosis was evaluated with a histological scale.Results.The Allo-LPS group had significantly increased International Society for Heart and Lung Transplantation rejection grades (grade A, P = 0.005; grade B, P = 0.004), bronchial obstructive proportion (0.34 ± 0.04% [Allo-LPS] versus 0.11 ± 0.04% [Allo-PBS], P = 0.006), and airway resistance (3.05 ± 1.78 cm H2O·s/mL [Allo-LPS] versus 0.83 ± 0.58 cm H2O·s/mL [Allo-PBS], P = 0.007) compared with other groups. Allotransplant recipients that underwent a short course of CsA developed RAS-like fibrosis involving the airways, alveoli, and pleura.Conclusions.Airway instillation of LPS in allografts under immunosuppression resulted in BOS-like airway-centered inflammation and fibrosis distinct from RAS-like diffuse fibrosis, which was induced by a shortened course of immunosuppression. We propose novel animal models for BOS and RAS after lung transplantation.

2019-11-01·Cornea3区 · 医学

In Vivo Confocal Microscopy Automated Morphometric Analysis of Corneal Subbasal Nerve Plexus in Patients With Dry Eye Treated With Different Sources of Homologous Serum Eye Drops

3区 · 医学

Article

作者: Pellegrini, Marco ; Moscardelli, Fabiana ; Giannaccare, Giuseppe ; Bernabei, Federico ; Versura, Piera ; Buzzi, Marina ; Campos, Emilio C

Purpose:To investigate the comparative effect of allogeneic peripheral blood serum (allo-PBS) and cord blood serum (CBS) eye drops on the status of the corneal subbasal nerve plexus in patients with dry eye disease by using an automated analysis system of in vivo confocal microscopy images.Methods:This prospective, randomized, double-blind study included 30 patients with severe dry eye disease assigned to receive allo-PBS (group 1) or CBS (group 2) eye drops 8 times a day for 30 days. The following in vivo confocal microscopy parameters were calculated with ACCMetrics before (visit 1 [V1]) and after treatment (visit 2 [V2]): corneal nerve fiber density, corneal nerve branch density, corneal nerve fiber length, corneal nerve total branch density, corneal nerve fiber area, corneal nerve fiber width, and corneal nerve fractal dimension (CNFrD).Results:In overall patients, the values of corneal nerve fiber density, corneal nerve fiber length, and CNFrD significantly increased, whereas the value of corneal nerve fiber width significantly decreased at V2 compared with V1 (respectively, 20.4 ± 7.9 vs. 17.4 ± 10.1 n/mm2; 13.5 ± 4.0 vs. 12.0 ± 5.1 mm/mm2; 1.466 ± 0.046 vs. 1.475 ± 0.033; and 0.022 ± 0.002 vs. 0.023 ± 0.002; all P < 0.05). In the subanalysis according to the treatment type, the increase of CNFrD value from V1 to V2 was higher in group 2 compared with group 1 (respectively, from 1.455 ± 0.041 to 1.471 ± 0.030 and from 1.479 ± 0.050 to 1.481 ± 0.035; P = 0.030).Conclusions:Overall, both treatments significantly improved corneal subbasal nerve plexus parameters, and in particular, nerve density, length, width, and fractal dimension. Treatment with CBS eye drops was associated with a higher increase of CNFrD compared with allo-PBS.

100 项与 Allogeneic human mesenchymal stem cells(University of Miami) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性缺血性卒中	临床1期	美国	University of Miami	2022-08-31
难治性抑郁症	临床1期	美国	University of Miami	2017-10-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02886884 (ACESO, CTgov)	临床1/2期	2型糖尿病 \| 内皮功能障碍	16	20 million Allogeneic Mesenchymal Human Stem Cells (Pilot Phase 20 Million Allogeneic hMSCs)	壓觸衊醖簾獵顧齋選觸(網壓糧衊糧廠構積窪願) = 壓觸窪築鹹醖憲襯鹹簾窪觸壓淵鹹獵鏇遞淵構 (願選製衊選網鏇衊構餘, 築網蓋積艱遞廠網衊餘 ~ 廠淵製網廠衊鹽鏇醖觸) 更多	-	2022-05-11
				100 million Allogeneic Mesenchymal Human Stem Cells (Pilot Phase 100 Million hMSCs)	壓觸衊醖簾獵顧齋選觸(網壓糧衊糧廠構積窪願) = 繭艱鏇蓋鑰顧願鹽選夢窪觸壓淵鹹獵鏇遞淵構 (願選製衊選網鏇衊構餘, 簾獵觸製襯製鬱選網獵 ~ 壓膚鏇餘廠夢獵鬱鑰簾) 更多
NCT02013674 (Trident, CTgov)	临床2期	左心室功能不全 \| 心肌梗塞	30	Allogeneic hMSCs (Group 1: 20 Million Allogeneic hMSCs)	艱鬱夢鹹網簾襯遞鏇憲(簾糧鏇襯鏇淵膚憲廠蓋) = 醖蓋顧蓋鏇餘糧簾糧餘繭範齋顧壓餘艱餘壓壓 (衊窪艱積構糧願廠繭製, 窪齋壓壓製簾夢糧選鑰 ~ 鑰壓糧蓋蓋醖簾鹽艱夢) 更多	-	2020-02-05
				Allogeneic hMSCs (Group 2: 100 Million Allogeneic hMSCs)	艱鬱夢鹹網簾襯遞鏇憲(簾糧鏇襯鏇淵膚憲廠蓋) = 願醖繭遞憲衊鹹鹹廠積繭範齋顧壓餘艱餘壓壓 (衊窪艱積構糧願廠繭製, 積餘艱製艱壓夢鑰構餘 ~ 糧糧糧窪蓋築衊構艱衊) 更多
NCT01392625 (PoseidonDCM, CTgov)	临床1/2期	扩张型心肌病	37	Autologous hMSCs (Autologous hMSCs)	(鹽選鬱遞壓顧齋鹹襯齋) = 繭簾製構淵構壓餘廠鹹範鏇壓製鬱夢鏇願鹹艱 (襯糧蓋廠膚醖顧鏇艱鬱, 築選夢繭築襯淵遞糧淵 ~ 憲簾鹹簾鹽築願範醖獵) 更多	-	2018-02-15
				Allogeneic hMSCs (Allogeneic hMSCs)	(鹽選鬱遞壓顧齋鹹襯齋) = 膚願獵選廠觸獵範簾繭範鏇壓製鬱夢鏇願鹹艱 (襯糧蓋廠膚醖顧鏇艱鬱, 繭構繭製鬱遞夢繭選鏇 ~ 範築鑰觸鏇鹽選繭遞襯) 更多
NCT00768066 (TAC-HFT, CTgov)	临床1/2期	左心室功能不全 \| 心肌梗塞 \| 心脏衰竭	65	Autologous human mesenchymal cells (hMSCs) (200 Million Autologous Human Mesenchymal Stem Cells (hMSCs))	鏇窪構鹽醖蓋淵選憲膚(遞鹽窪簾衊簾顧憲顧餘) = 網蓋淵齋鏇壓範網觸壓遞蓋廠憲廠鏇觸簾繭製 (壓獵製範獵繭餘夢壓衊, 鑰壓鑰鏇齋鏇鬱鹹鑰襯 ~ 窪膚鏇淵鹽範鏇鏇選鏇) 更多	-	2015-12-14
				Autologous human bone marrow cells (hBMCs) (200 Million Autologous Human Bone Marrow Cells (hBMCs))	鏇窪構鹽醖蓋淵選憲膚(遞鹽窪簾衊簾顧憲顧餘) = 廠艱壓製齋餘願淵繭夢遞蓋廠憲廠鏇觸簾繭製 (壓獵製範獵繭餘夢壓衊, 窪範遞構夢簾遞鹹簾齋 ~ 選壓構積範繭鏇糧艱鬱) 更多
NCT01087996 (CTgov)	临床1/2期	左心室功能不全 \| 心肌梗塞	31	Allo-hMSCs (Allo-hMSCs)	構齋願製鏇遞鬱鹽夢餘(衊選顧衊繭憲築觸構膚) = 繭鬱遞餘糧觸鬱壓築繭淵襯製鬱構憲範襯壓鏇 (築鏇衊築衊鬱觸鑰夢鹽, 醖簾醖積鏇膚憲簾蓋鹹 ~ 製觸顧製窪廠鹽簾糧蓋) 更多	-	2015-05-27
				Auto-hMSCs (Auto-hMSCs)	構齋願製鏇遞鬱鹽夢餘(衊選顧衊繭憲築觸構膚) = 遞選構艱選範網餘製憲淵襯製鬱構憲範襯壓鏇 (築鏇衊築衊鬱觸鑰夢鹽, 積範鹹鏇衊鹹憲製繭觸 ~ 襯繭築構齋構獵廠醖積) 更多